Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION Advisory-committee question list that exposes a weak secondary endpoint arrived with a CRL citing manufacturing, not efficacy for 505(b)(2) development lead. That is a Pharma & Life Sciences CMC and Development Pathways decision on to drop a secondary in a labeling team facing a boxed-warning debate.

DECISION 505(b)(2) development lead in a labeling team facing a boxed-warning debate must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using advisory-committee question list that exposes a weak secondary endpoint after a CRL citing manufacturing, not efficacy.

HYPOTHESES TO TEST 1. The population in advisory-committee question list that exposes a weak secondary endpoint is the one a CRL citing manufacturing, not efficacy named, so Proceed under protocol follows for this CMC and Development Pathways file. 2. The population in advisory-committee question list that exposes a weak secondary endpoint is adjacent only to a CRL citing manufacturing, not efficacy; Pause the pathway is the honest Pharma & Life Sciences call. 3. A labeling team facing a boxed-warning debate already contained a CRL citing manufacturing, not efficacy before advisory-committee question list that exposes a weak secondary endpoint arrived; no new CMC and Development Pathways path. 4. Provenance on advisory-committee question list that exposes a weak secondary endpoint after a CRL citing manufacturing, not efficacy is broken; do not pick Proceed under protocol or Pause the pathway yet.

ANALYSIS REQUIRED 1. Trace CMC, labeling, or pharmacovigilance facts in advisory-committee question list that exposes a weak secondary endpoint after a CRL citing manufacturing, not efficacy. 2. Separate an isolated adverse event from a systemic quality issue. 3. Test a protocol deviation versus a safety signal versus a filing gap on to drop a secondary. 4. For this Pharma & Life Sciences CMC and Development Pathways file, read advisory-committee question list that exposes a weak secondary endpoint against a CRL citing manufacturing, not efficacy and write the one fact that would move to drop a secondary for 505(b)(2) development lead.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / CMC and Development Pathways packet (advisory-committee question list that exposes a weak secondary endpoint after a CRL citing manufacturing, not efficacy). If advisory-committee question list that exposes a weak secondary endpoint cannot force a Pharma & Life Sciences label under CMC and Development Pathways, stop. If advisory-committee question list that exposes a weak secondary endpoint after a CRL citing manufacturing, not efficacy cannot support Proceed under protocol versus Pause the pathway on this Pharma & Life Sciences CMC and Development Pathways close, 505(b)(2) development lead must state the unresolved clinical or safety evidence requirement explicitly.